Cargando…

Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma

Multiple myeloma remains an incurable disease despite the introduction of the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide and the proteasome inhibitor bortezomib that have improved the outcome of patients with both newly diagnosed and relapsed/refractory disease. However, patients wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Terpos, Evangelos, Kanellias, Nikolaos, Christoulas, Dimitrios, Kastritis, Efstathios, Dimopoulos, Meletios A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656921/
https://www.ncbi.nlm.nih.gov/pubmed/23690693
http://dx.doi.org/10.2147/OTT.S34498
_version_ 1782270078421565440
author Terpos, Evangelos
Kanellias, Nikolaos
Christoulas, Dimitrios
Kastritis, Efstathios
Dimopoulos, Meletios A
author_facet Terpos, Evangelos
Kanellias, Nikolaos
Christoulas, Dimitrios
Kastritis, Efstathios
Dimopoulos, Meletios A
author_sort Terpos, Evangelos
collection PubMed
description Multiple myeloma remains an incurable disease despite the introduction of the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide and the proteasome inhibitor bortezomib that have improved the outcome of patients with both newly diagnosed and relapsed/refractory disease. However, patients who relapse after treatment with these agents or are refractory to them represent an unmet need and highlight the necessity for the development of novel anti-myeloma agents. Pomalidomide is an IMiD, structurally related to thalidomide, with enhanced antiangiogenic, antineoplastic, and anti-inflammatory properties and exhibiting potent anti-myeloma activity in vitro and in vivo. Pomalidomide has shown remarkable activity in patients who were refractory to both bortezomib and lenalidomide in Phase II and III studies. This paper reviews the chemistry and mechanisms of action of pomalidomide as well as all the available data from clinical trials on pomalidomide use in patients with refractory/relapsed multiple myeloma.
format Online
Article
Text
id pubmed-3656921
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-36569212013-05-20 Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma Terpos, Evangelos Kanellias, Nikolaos Christoulas, Dimitrios Kastritis, Efstathios Dimopoulos, Meletios A Onco Targets Ther Original Research Multiple myeloma remains an incurable disease despite the introduction of the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide and the proteasome inhibitor bortezomib that have improved the outcome of patients with both newly diagnosed and relapsed/refractory disease. However, patients who relapse after treatment with these agents or are refractory to them represent an unmet need and highlight the necessity for the development of novel anti-myeloma agents. Pomalidomide is an IMiD, structurally related to thalidomide, with enhanced antiangiogenic, antineoplastic, and anti-inflammatory properties and exhibiting potent anti-myeloma activity in vitro and in vivo. Pomalidomide has shown remarkable activity in patients who were refractory to both bortezomib and lenalidomide in Phase II and III studies. This paper reviews the chemistry and mechanisms of action of pomalidomide as well as all the available data from clinical trials on pomalidomide use in patients with refractory/relapsed multiple myeloma. Dove Medical Press 2013-05-10 /pmc/articles/PMC3656921/ /pubmed/23690693 http://dx.doi.org/10.2147/OTT.S34498 Text en © 2013 Terpos et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Terpos, Evangelos
Kanellias, Nikolaos
Christoulas, Dimitrios
Kastritis, Efstathios
Dimopoulos, Meletios A
Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
title Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
title_full Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
title_fullStr Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
title_full_unstemmed Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
title_short Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
title_sort pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656921/
https://www.ncbi.nlm.nih.gov/pubmed/23690693
http://dx.doi.org/10.2147/OTT.S34498
work_keys_str_mv AT terposevangelos pomalidomideanoveldrugtotreatrelapsedandrefractorymultiplemyeloma
AT kanelliasnikolaos pomalidomideanoveldrugtotreatrelapsedandrefractorymultiplemyeloma
AT christoulasdimitrios pomalidomideanoveldrugtotreatrelapsedandrefractorymultiplemyeloma
AT kastritisefstathios pomalidomideanoveldrugtotreatrelapsedandrefractorymultiplemyeloma
AT dimopoulosmeletiosa pomalidomideanoveldrugtotreatrelapsedandrefractorymultiplemyeloma